Si Bone Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Si Bone Inc 's ROA in the second quarter of 2026?
Si Bone Inc recorded a cumulative net loss of $-15 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -5.95%.

However, within the Healthcare sector 267 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3076, from total ROA ranking in the first quarter of 2026 at 3659.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	16.29 %	7.27 %	3.65 %	3.91 %	2.82 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-15	-17	-19	-22	-24
Return On Assets (TTM)	-5.95 %	-7.06 %	-8.14 %	-9.45 %	-10.42 %
SIBN's Total Ranking	# 3076	# 3659	# 3263	# 3313	# 3382
Total Assets (TTM) in million	268	243	239	234	230
Seq. Total Assets Change	10.27 %	1.75 %	1.83 %	1.79 %	1.71 %
Seq. Net Income Change	-	-	-	-	-

SIBN's 5 Years Annual ROA >> Back to SIBN Management Effectiveness >> Compare SIBN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 84
Sector	# 268
Overall	# 3015

Return On Assets Statistics
High	Average	Low
-6.07 %	-23.13 %	-37.33 %
(Jun 30 2026)		(Sep 30 2022)

News about Si bone inc Return on Assets ROA

The iFuse Bedrock Granite System Navigating Challenges and Opportunities in the Changing Landscape of Medical Device ...

In the competitive landscape of medical devices, companies are continually grappling with regulatory hurdles and market dynamics that can significantly impact their growth trajectories. Among those navigating this challenging terrain is SI-BONE, a company specializing in surgical implants for the treatment of the sacroiliac joint and other orthopedic applications. Recently, SI-BONE announced that its iFuse Bedrock Granite system has received Transitional Pass-Through Payment Status, a development that could have far-reaching implications for both patients and the broader orthopedic market. Breakthrough Device Designation: A Major MilestoneThe iFuse Bedrock Granite system has achieved Breakthrough Device Designation status, which is a recognition granted by the FDA to devices that offer more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. This designation is noteworthy not only for the potential impact on patient outcomes but also for the strategic advantage it provides in terms of regulatory approval and market access.

SI-BONE, Inc. Receives FDA Clearance and Breakthrough Status for Revolutionary Pelvic Fracture Fixation System

SANTA CLARA, Calif., Aug. 20, 2024 - SI-BONE, Inc. (Nasdaq: SIBN), a leading medical device company specializing in surgical solutions for sacropelvic disorders, has recently obtained FDA 510(k) clearance for its innovative iFuse TORQ TNT Implant System (TNT). This breakthrough technology is specifically designed to address the anatomical and bone mineral density requirements of the sacrum and ilium and aims to revolutionize the field of pelvic fragility fracture fixation and sacroiliac joint fusion.
The company s latest achievement marks a significant milestone for SI-BONE, Inc. and showcases their commitment to advancing surgical solutions for patients suffering from sacropelvic disorders. The clearance from the U.S. Food and Drug Administration allows the TNT implant system to enter the market and potentially transform the treatment landscape for individuals experiencing pelvic fractures.

Financial Statements
Si Bone Inc 's Assets	$ 268 million	SIBN's Balance sheet
Si Bone Inc 's Income	$ -4 million	Quarterly SIBN's Income Statement
SIBN's Income by Division		See SIBN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	3.65 %	0.77 %	48.14 %	-17.49 %	-16.26 %
Total Assets in million	239	230	228	154	187
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-19	-31	-43	-61	-57
Annual Return On Assets	-7.92 %	-13.43 %	-18.97 %	-39.73 %	-30.28 %

SIBN's 5 Years Annual ROA >> Back to SIBN Management Effectiveness >> Compare SIBN ROA to its Competitors

More Return On Assets Ratios
SIBN's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SIBN's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SIBN's Competitors
Subscribers only: Roa for Si Bone Inc 's Suppliers
Subscribers only: Return On Assets for SIBN's Customers

You may also want to know
SIBN's Roi	SIBN's Inventory Turnover Ratio	SIBN's Growth Rates	SIBN's Dividend Comparisons
	SIBN's Profitability Ratios	SIBN's Asset Turnover Ratio	SIBN's Dividend Growth
SIBN's Roe	SIBN's Valuation Ratios	SIBN's Financial Strength Ratios	SIBN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:37:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.